Evidence map›Paper›PMID 37231491›Full record

ArticleAlzheimer's research & therapy2023

Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [

Antoinette O'Connor, David M Cash, Teresa Poole, Pawel J Markiewicz, Maggie R Fraser, Ian B Malone, Jieqing Jiao, Philip S J Weston, Shaney Flores, Russ Hornbeck and 6 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Is Alzheimer disease a disease?Nature reviews. Neurology · 2024
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Antoinette O'Connor *Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK. Antoinette.o'connor@ucl.ac.uk.
David M Cash *Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Teresa PooleDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Pawel J MarkiewiczCentre for Medical Image Computing, Medical Physics and Biomedical Engineering, UCL, London, UK.
Maggie R FraserDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Ian B MaloneDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Jieqing JiaoCentre for Medical Image Computing, Medical Physics and Biomedical Engineering, UCL, London, UK.
Philip S J WestonDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Shaney FloresDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Russ HornbeckDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Eric McDadeDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Michael SchöllDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Brian A GordonDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Randall J BatemanDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Tammie L S BenzingerDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Nick C FoxDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MARCUS, DANIEL SCOTT · 2008 to 2009
$6.1M
PET Imaging of Neuroinflammation in Genetic Alzheimer's DiseaseR01AG052550 · NIA · WASHINGTON UNIVERSITY · PI Beau M Ances, Tammie Lee Smith Benzinger · 2018 to 2026
$4.2M
Neuroimaging Markers of Emerging Dysfunction In Preclinical Alzheimer DiseaseK01AG053474 · NIA · WASHINGTON UNIVERSITY · PI GORDON, BRIAN ANDREW · 2017 to 2021
$623k
Department of HealthMedical Research CouncilNIA NIH HHS K01 AG053474NIA NIH HHS R01 AG052550NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIA NIH HHS UFAG032438NIH HHS K01AG053474
6 · The paper itself

Abstract

Cortical tau accumulation is a key pathological event that partly defines Alzheimer's disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understanding of the timing and pattern of early tau deposition in AD and how this may be tracked in vivo is needed. Data from 59 participants involved in two longitudinal cohort studies of autosomal dominant AD (ADAD) were used to investigate whether tau PET can detect and track presymptomatic change; seven participants were symptomatic, and 52 were asymptomatic but at a 50% risk of carrying a pathogenic mutation. All had baseline flortaucipir (FTP) PET, MRI and clinical assessments; 26 individuals had more than one FTP PET scan. Standardised uptake value ratios (SUVRs) in prespecified regions of interest (ROIs) were obtained using inferior cerebellar grey matter as the reference region. We compared the changes in FTP SUVRs between presymptomatic carriers, symptomatic carriers and non-carriers, adjusting for age, sex and study site. We also investigated the relationship between regional FTP SUVRs and estimated years to/from symptom onset (EYO). Compared to both non-carriers and presymptomatic carriers, FTP SUVRs were significantly higher in symptomatic carriers in all ROIs tested (p < 0.001). There were no significant regional differences between presymptomatic carriers and non-carriers in FTP SUVRs, or their rates of change (p > 0.05), although increased FTP signal uptake was seen posteriorly in some individuals around the time of expected symptom onset. When we examined the relationship of FTP SUVR with respect to EYO, the earliest significant regional difference between mutation carriers and non-carriers was detected within the precuneus prior to estimated symptom onset in some cases. This study supports preliminary studies suggesting that presymptomatic tau tracer uptake is rare in ADAD. In cases where early uptake was seen, there was often a predilection for posterior regions (the precuneus and post-cingulate) as opposed to the medial temporal lobe, highlighting the importance of examining in vivo tau uptake beyond the confines of traditional Braak staging.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCarbolinesHumansLongitudinal StudiesPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinestau Proteins

Identifiers

PMID37231491
PMCPMC10210376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.